Celgene's Revlimid survival data evaluated in previously treated multiple myeloma

By Elaine Rigoli

Tampa, Fla., June 6 - Celgene Corp. said updated clinical data from a North American phase 3 trial reported overall survival in addition to median time to disease progression in patients receiving lenalidomide plus dexamethasone compared to patients receiving dexamethasone plus a placebo.

Key findings included the following:

• The median overall survival with lenalidomide plus dexamethasone was 29.6 months, compared with 20.2 months for dexamethasone plus a placebo;

• The median time-to-disease progression with lenalidomide plus dexamethasone was 11.1 months, compared with 4.7 months for dexamethasone plus a placebo;

• Best response rate with lenalidomide plus dexamethasone was 59.4%, compared with 21.1% for dexamethasone plus a placebo;

• Complete response rate with lenalidomide plus dexamethasone was 12.9%, compared with 0.6% for dexamethasone plus a placebo.

The updated clinical data from the pivotal international phase 3 trial (MM-010) reported overall survival, but median overall survival has not yet been reached, according to a news release.

Celgene, based in Summit, N.J, is an integrated global pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.